Venetoclax - AbbVie/Genentech

Drug Profile

Venetoclax - AbbVie/Genentech

Alternative Names: A-1195425.0; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
  • Developer AbbVie; Dana-Farber Cancer Institute; Genentech; Janssen Research & Development; Merck & Co; Nantes University Hospital; Pharmacyclics; Roche
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Preregistration Acute myeloid leukaemia
  • Phase III Mantle-cell lymphoma; Multiple myeloma
  • Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I Cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 23 Jul 2018 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain (PO) (NCT03484520)
  • 16 Jul 2018 Preliminary efficacy data from a phase I trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 12 Jul 2018 Phase-II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater, Recurrent) in USA (PO) (NCT03584009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top